4.8 Article

A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer

期刊

NATURE GENETICS
卷 44, 期 12, 页码 1326-1329

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/ng.2437

关键词

-

资金

  1. European Union [202059]
  2. Urological Research Foundation [U01 CA089600, P50 CA90386, P30 CA60553]
  3. Health Technology Assessment Programme [96/20/06, 96/20/99]
  4. Department of Health, England
  5. Cancer Research UK [C522/A8649]
  6. Medical Research Council of England [G0500966_ID-75466]
  7. National Cancer Research Institute (NCRI), UK
  8. Southwest National Health Service Research and Development
  9. NCRI (ProMPT) study
  10. Cambridge and Oxford British Medical Research Council grants from the National Institute for Health Research

向作者/读者索取更多资源

In Western countries, prostate cancer is the most prevalent cancer of men and one of the leading causes of cancer-related death in men. Several genome-wide association studies have yielded numerous common variants conferring risk of prostate cancer. Here, we analyzed 32.5 million variants discovered by whole-genome sequencing 1,795 Icelanders. We identified a new low-frequency variant at 8q24 associated with prostate cancer in European populations, rs188140481[A] (odds ratio (OR) 2.90; P-combined = 6.2 x 10(-34)), with an average risk allele frequency in controls of 0.54%. This variant is only very weakly correlated (r(2) <= 0.06) with previously reported risk variants at 8q24, and its association remains significant after adjustment for all known risk-associated variants. Carriers of rs188140481[A] were diagnosed with prostate cancer 1.26 years younger than non-carriers (P = 0.0059). We also report results for a previously described HOXB13 variant (rs138213197[T]), confirming it as a prostate cancer risk variant in populations from across Europe.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据